T42肽对CD133阳性肝癌干细胞小鼠异位荷瘤能力的影响

目的:观察重组肿瘤抑素T42肽对人肝癌干细胞(liver cancer stem cells,LCSCs)体外血管生成及小鼠体内荷瘤能力的影响。方法:培养人肝癌细胞系SMMC-7721,免疫磁珠法提取富集CD133 + (Cluster of Differentiation 133)肝癌干细胞LCSCs;构...     

缺氧增加肝癌细胞胚胎干细胞基因表达促进恶性转化

目的 研究缺氧对原发性肝癌恶性表型的影响及相关机制.方法 建立体内、外缺氧模型,比较缺氧对MHCC97H肝癌细胞成瘤和侵袭转移能力的影响,并通过检测细胞增殖周期,CD90、CD133标记的肝癌干细胞数量以及胚胎干细胞(embryonic stem cell,ES)样基因Oct4,Nanog,Sox2等的表达分析缺氧对肝癌细胞生物学特性的影响.结果 缺氧促进MHCC97H肝癌细胞运动(t=2.792,P=0.023)、侵袭(t=7.624,P＜0.0001)、转移(x~2=5.507,P=0.031)潜能,并增加软琼脂集落形成(t=3.292,P=0.011)和裸鼠皮下成瘤率(x~2=8.571,P=0.015).在缺氧环境中,MHCC97H肝癌细胞增殖能力受到抑制,G1期细胞比例显著增加,Oct4,Nanog,Sox2等基因表达明显上调.结论 缺氧促进MHCC97H肝癌细胞成瘤和转移等恶件表型与获得胚胎干细胞样特征有关.     

人胆囊癌细胞系GBC-SD中侧群细胞的耐药性研究

目的 研究人胆囊细胞系GBC-SD中侧群细胞(side population cells,SP)的耐药特性,并探讨其耐药机制.方法 利用流式细胞术分选SP、非SP细胞,采用MTT检测2种细胞亚群对5种化疗药物吉西他滨、顺铂、5-氟尿嘧啶、表阿霉素、米托蒽醌的药物敏感性;利用流式细胞术检测吉西他滨处理的人胆囊癌细胞系GBC-SD中SP细胞比例的变化,并通过RT-PCR、Western印迹检测SP、非SP细胞亚群中ABCG2 mRNA和蛋白的表达.结果 吉西他滨、顺铂、5-氟尿嘧啶、米托蒽醌以对胆囊癌细胞系GBC-SD的IC50浓度分别作用SP、非SP细胞亚群1 d后,SP细胞的增殖能力高于非SP细胞,两组之间的差异具有统计学意义(P<0.05),而表阿霉素处理水平的两组间差异无统计学意义(P>0.05);人胆囊癌细胞系GBC-SD经过吉西他滨处理3周后,SP细胞的比例显著升高(8.02%±0.13%比0.62%±0.08%,P<0.05),且SP细胞明显高表达ABCG2基因.结论 人胆囊癌细胞系GBC-SD中SP细胞具有类似干细胞的耐药特性,耐药基因ABCG2高表达是其耐药的重要机制.

Abstract：

Objective To investigate the drug resistance of side population cells in human gallbladder cancer cell line GBC-SD and explore its mechanism. Methods Drug sensitivity assays of 5chemotherapeutic agents were performed on side population cells (SP) and non-SP cells of GBC-SD.GBC-SD was cultured and then treated with the chemotherapeutic agent gemcitabine. The frequency of SP by FACS was measured. RT-PCR and Western blotting were used to detect the expression of AB-CG2 in both the SP and the corresponding non-SP subsets. Results After 1 d treatment with 4 chemotherapeutic agents (gemcitabine, cisplatin, 5-fluorouracil and mitoxantrone) in IC50 concentration to GBC-SD cell line, the reproductive ability of SP was higher than that of non-SP (P<0.05). However, statistical significance was not achieved when compared with epirubicin (P>0.05). The percentage of SP in GBC-SD treated with chemotherapeutic agent gemcitabine after 3 weeks was sharply elevated by FACS (8.02% ±0.13% vs 0.62% ±0.08%, P<0.05), and the expression of ABCG2mRNA and protein were increased in SP as compared with non-SP. Conclusion SP from human gallbladder cancer cell line GBC-SD, like stem cell, showed a heighten resistance to drugs. Increased expression of ABCG2 was largely responsible for the multi-drug resistance.     

半乳糖凝集素1在CD133+肺腺癌细胞中的表达和功能

目的 观察肺腺癌CD133+细胞中半乳糖凝集素1(Galectin-1)的表达和功能.方法 磁珠分选出9例患者肺腺癌中CD133+细胞并以流式细胞术检测分选效率,荧光实时定量聚合酶链反应(fqRT-PCR)、Western blot和酶联免疫吸附试验(ELISA)检测CD133+细胞中或上清液中Galectin-1的表达,Galectin-1小干扰RNA(siRNA)转染CD133+细胞后检测其对肿瘤细胞生长以及克隆形成能力的影响.予裸鼠皮下注射Galectin-1 siRNA转染后的CD133+细胞并观察肿瘤的生长.结果 流式细胞术结果表明磁珠分选出的细胞中CD133+细胞率为92.6%.fqRT-PCR和Western blot检测结果显示Galectin-1在CD133+细胞中的表达量分别是CD133-细胞中的1.748倍和1.135倍.体外显示发现下调CD133+细胞中Galectin-1表达后肿瘤细胞的增殖率为(36.75±1.35)%,对照组为(92.31±0.78)%,差异有统计学意义(P＜0.05).结论 Galectin-1在肺腺癌干细胞中高表达,并能促进肺腺癌干细胞的生长增殖.

Abstract：

Objective To investigate the expression and function of Galectin-1 in CD133+ pulmonary adenocarcinoma cells. Methods CD133 + cells were separated by magnetic activated cell sorting (MACS) from excised pulmonary adenocarcinoma speciments of 9 patiens. The proportion of CD133 + cells was measured by flow cytometry (FCM). The expression of Galectin-1 in CD133 + or CD133 - cells was quantitated by fluorescent quantitation real-time polymerase chain reaction (fqRT-PCR), Western blotting and enzyme linked immunosorbent assay (ELISA) respectively. CD133 + cells were transfected with small interfering RNA (siRNA) of Galectin-1 to study the effect of Galectin-1 inhibition on cancer cells growth and clonality. Tumorigenesis in nude mice was also performed in vivo. Results 92.6% cells separated by MACS were positive for CD133, which was proved by FCM. The expression of Galectin-1 in CD133 + cells was 1. 748 folds and 1. 135 folds higher than that in CD133 - celts detected by fqRT-PCR and Western blot respectively. Downregulation of Galectin-1 ex vivo also resulted in (36. 75 ±: 1.35 ) % decrease of proliferation rate of cancer cells. Conclusion Galectin-1 which can be efficiently inhibited by Galectin-1 siRNA was significantly highly expressed in CD133 + cells and associated with the proliferation and clonality of CD133 + cells.     

人瘢痕疙瘩来源干细胞的生物学特性鉴定

目的 分析人瘢痕疙瘩来源干细胞的生物学特性,为进一步研究该细胞在瘢痕疙瘩形成中的作用提供参考.方法 以人瘢痕疙瘩为研究对象,采用酶消化法及传代培养法分离筛选瘢痕疙瘩干细胞.选取原代和(或)第3代贴壁细胞进行生物学特性鉴定:加入CD29-藻红蛋白(PE)、CD34-PE、CD44-异硫氰酸荧光素(FITC)、CD90-FITC、CD45-多甲藻黄素叶绿素蛋白抗体,流式细胞仪检测细胞表面分子标记物CD29、CD34、CD44、CD45及CD90的表达及细胞周期;加入小鼠抗人细胞角蛋白19(CK19)即用型单克隆抗体、鼠抗波形蛋白即用型单克隆抗体,免疫细胞化学法检测CK19、波形蛋白的表达;RT-PCR检测细胞Oct4的表达.取第1代细胞,应用成骨细胞、成脂肪细胞、软骨细胞诱导分化培养液进行诱导分化实验,观察细胞的多向分化能力.结果 传代培养后,细胞形态较为均一,以梭形为主,排列不规则.流式细胞仪检测表明,该细胞高表达CD29、CD44、CD90等间充质干细胞表面标记物,低表达CD34、CD45等造血干细胞表面标记物.细胞周期分析显示67.66%的细胞处于G0/G1期,26.24%的细胞处于G2/M期,6.11%的细胞处于S期.免疫细胞化学法检测显示细胞波形蛋白表达呈阳性、CK19表达呈阴性.RT-PCR法检测显示细胞Oct4表达呈阳性.诱导分化实验表明,细胞可向成骨细胞、软骨细胞和成脂肪细胞分化,具有多向分化潜能.结论 人瘢痕疙瘩内存在间充质样干细胞,这种干细胞可能在瘢痕疙瘩形成中发挥重要作用.

Abstract：

Objective To investigate the biological characteristics of human keloid-derived stem cells (KDSC) in order to further research its role in keloid pathogenesis. Methods Human keloid specimens were harvested to isolate and select KDSC by enzyme digestion and subculturing. Primary and (or) the third generation of KDSC were collected for identification of biological characteristics as follows. (1) After addition of mouse anti-human monoclonal fluorescent antibodies (CD29-PE,CD34-PE,CD44-FITC,CD90-FITC,CD45-PerCP),the expression of cell surface antigen phenotype (CD29,CD34,CD44,CD45,CD90) as well as cell cycle was analyzed by flow cytometry. (2) After addition of mouse anti-human cell keratin (CK19) monoclonal antibody and mouse anti-human vimentin monoclonal antibody,the expression level of CK19 and vimentin was respectively determined with immunocytochemical method. RT-PCR was used to detect the expression of Oct4. The multipotent differentiation capacity of the first generation KDSC was observed with osteogenic,chondrogenic and adipogenic nutrient media. Results After being subcultured,the sizes of cells were similar,and the majority of them were spindle-shaped with disorderly arrangement. The cells highly expressed typical surface markers of mesenchymal stem cells (such as CD29,CD44,and CD90,etc.) with low expression of hematopoietic stem cell surface markers (such as CD34,CD45,etc.). 67.66% of cells were in G0/G1 phase,26.24% of cells were in G2/M phase,and 6.11% of cells were in S phase. Vimentin was positively expressed in KDSC while CK19 was negatively expressed. The expression of Oct4 was also positive. After being cultured in inducing differentiation media,the cells could differentiate into osteoblasts,chondrocytes,and adipocytes. Conclusions Stem cells existing in human keloid,which are similar to mesenchymal stem cells,may play an important role in keloid pathogenesis.     

沉默NANOG基因表达对侧群表型肝癌干细胞化疗耐药的影响

目的观察沉默NANOG基因对侧群表型肝癌干细胞化疗耐药的影响,初步探讨提高肝癌化疗效果的新方法。 方法基于侧群（SP）细胞分选法,采用流式细胞术从肝癌细胞Hep3B中分选SP细胞和非侧群（NSP）细胞,通过特异性靶向NANOG基因的siRNA沉默SP细胞中NANOG基因表达,MTT法检测SP细胞对化疗药物阿霉素（DOX）的敏感性,实时荧光定量PCR（real-time PCR）和免疫印迹（Western blotting）检测NANOG和耐药相关基因ABCB1的表达。 结果（1）肝癌细胞Hep3B中分选的SP细胞比例为（13.3±1.8）%。（2）MTT法结果显示DOX处理后SP细胞存活率为（65.3±5.4）%,NSP细胞存活率为（41.2±4.7）%;SP细胞对DOX的耐药性高于NSP细胞（P<0.05）。（3）NANOG和ABCB1 mRNA在SP细胞中的表达水平分别是NSP细胞的4.5、4.0倍;NANOG和ABCB1蛋白在SP细胞中表达水平分别是NSP细胞的4.2、3.6倍,差异均有统计学意义（P<0.05）。（4）RNAi沉默NANOG表达后,siNANOG组SP细胞NANOG、ABCB1的mRNA和蛋白表达水平均较Mock组和siNC组明显下降（P<0.05）,SP细胞对阿霉素DOX的耐药性显著降低（P<0.05）。 结论NANOG基因在维持SP表型肝癌干细胞耐药性起重要作用,沉默NANOG表达后SP细胞耐药性受到抑制,可能与ABCB1表达下调有关。     

CD34+细胞在干细胞旁分泌下向内皮细胞分化的研究

目的 探讨人脐血CD34+细胞在脐带间充质干细胞(UC-MSCs)旁分泌作用下向内皮细胞诱导分化的可行性.方法 收集20份脐血,体积(103.80±19.77)ml.免疫磁珠(MACS)分选CD34+细胞;取脐带用消化贴壁法获得UC-MSC.流式鉴定干细胞表型.实验分单纯培养组、诱导组、共培养组.结果 流式鉴定CD34+细胞纯度(95.02±3.81)%.培养14 d流式检测共培养组表达CD31、CD144、VWF分别为(65.43±5.61)%、(54.40±4.13)%、(47.53±3.96)%(与单纯培养组比较P＜0.05),部分表达CD34,阴性表达CD45,这与诱导组及成熟脐静脉内皮细胞表达率一致.结论 UC-MSCs旁分泌作用与外源性细胞因子都具有促分化作用,均能使脐血CD34+细胞向内皮细胞分化.

Abstract：

Objective To study whether the paracrine action of umbilical cord-derived mesenchymal stem cells (UC-MSC) can induce differentiation of human umbilical cord blood-derived CD34+ cells into endothelial cells in vitro. Methods The 20 fresh umbilical cord blood samples were collected with volume of (103. 80 ± 19. 77) ml. CD34+ cells were isolated from the mononuclear cells by magnetic activated cell sorting system (MACS) , and mesenchymal stem cells (MSCs) were isolated from umbilical cord by collagenase and trypsin digestion. Three groups were set up: CD34+ cells pure culture group, cytokineinduced group and two stem cells co-culture group with noncontact. Results The average purity of enriched CD34+ cells as assessed by FACS was (95. 02 ± 3. 81) %. Freshly isolated CD34+ cells were small and round which suspended in culture medium. Attached cord-like structure cells of CD34+ cells appeared after 7 days coculture with noncontacted MSC, and when the CD34+ cells grew into large number, they formed colonies. These cells expressed endothelial specific markers, including CD144 (54. 40 ±4. 13)% ,vWF (47. 53 ± 3. 96) % , CD31 (65. 43 ± 5. 61) % ( P ＜ 0. 05, as compared with CD34+ cells pure culture group) , partially expressed CD34 and, the leukocyte common antigen CD45 was negatively expressed.Conclusion Human umbilical cord blood-derived CD34+ cells could be induced into endothelial cells under the paracrine action of umbilical cord-derive mesenchymal stem cells which has the same effect of cytokines.     

吉西他滨耐药人胰腺癌细胞株的建立及其与肿瘤干细胞的相关性研究

Objectives To establish a gemcitabine-resistant pancreatic cancer cell line SW1990/ GZ,and to explore the relationship between drug-resistant cell line SW1990/GZ and pancreatic cancer stem cell. Methods Gemcitabine-resistant pancreatic cancer cell line SW1990/GZ was obtained by treating parental cell line SW1990 in vitro with increasing dosage of gemcitabine in culture medium intermittently for 24 weeks. Stable cultures were obtained which were 77. 2-fold increased in resistance relative to parental cells. Gene expressions of ABCB1/MDR1, ABCC1/MRP and ABCG2/BCRP were determined by real-time PCR. Tumorigenic potential was performed by nude mice xenograft transplant experiments. Side population analysis and CD24CD44 positive cells explore were determined by flow cytometry to examine cancer stem cell proportion. Results Gemcitabine-resistant cell line SW1990/GZ underwent obvious morphological and functional changes. Compared with the parental cell line,SW1990/GZ cell was small and turned into round shape. SW1990/GZ had a higher gene expression level of ABCB1/MDR1, ABCC1/MRP and ABCG2/BCRP than SW1990(P <0. 01). Nude mice xenograft transplant experiments showed that only 1 x 105 SW1990/GZ cells were sufficient for tumor formation, whereas an injection of 1 x 105 SW1990 cells did not initiate tumors. Flow cytometry analysis showed that SP proportion in SW1990/GZ was (11.0±1.0)%, whereas in parental SW1990 it was ( 4. 6 ± 0. 9 ) % , CD44CD24 positive cells was (8. 73±0. 81) % in SW1990/GZ, whereas (1.1±0. 4)% in SW1990. Conclusions Gemcitabine-resistant cell line SW1990/GZ has a higher proportion of pancreatic cancer stem cells compared to its parental cell line SW1990. CD44 is mainly responsible for acquired drug resistance,which can be a potential target to overcome acquired drug resistance in pancreatic cancer.     

吉西他滨耐药人胰腺癌细胞株的建立及其与肿瘤干细胞的相关性研究

Objectives To establish a gemcitabine-resistant pancreatic cancer cell line SW1990/ GZ,and to explore the relationship between drug-resistant cell line SW1990/GZ and pancreatic cancer stem cell. Methods Gemcitabine-resistant pancreatic cancer cell line SW1990/GZ was obtained by treating parental cell line SW1990 in vitro with increasing dosage of gemcitabine in culture medium intermittently for 24 weeks. Stable cultures were obtained which were 77. 2-fold increased in resistance relative to parental cells. Gene expressions of ABCB1/MDR1, ABCC1/MRP and ABCG2/BCRP were determined by real-time PCR. Tumorigenic potential was performed by nude mice xenograft transplant experiments. Side population analysis and CD24CD44 positive cells explore were determined by flow cytometry to examine cancer stem cell proportion. Results Gemcitabine-resistant cell line SW1990/GZ underwent obvious morphological and functional changes. Compared with the parental cell line,SW1990/GZ cell was small and turned into round shape. SW1990/GZ had a higher gene expression level of ABCB1/MDR1, ABCC1/MRP and ABCG2/BCRP than SW1990(P <0. 01). Nude mice xenograft transplant experiments showed that only 1 x 105 SW1990/GZ cells were sufficient for tumor formation, whereas an injection of 1 x 105 SW1990 cells did not initiate tumors. Flow cytometry analysis showed that SP proportion in SW1990/GZ was (11.0±1.0)%, whereas in parental SW1990 it was ( 4. 6 ± 0. 9 ) % , CD44CD24 positive cells was (8. 73±0. 81) % in SW1990/GZ, whereas (1.1±0. 4)% in SW1990. Conclusions Gemcitabine-resistant cell line SW1990/GZ has a higher proportion of pancreatic cancer stem cells compared to its parental cell line SW1990. CD44 is mainly responsible for acquired drug resistance,which can be a potential target to overcome acquired drug resistance in pancreatic cancer.     

细胞株源人前列腺肿瘤干细胞的分选与鉴定

目的:论证人前列腺癌(prostate cancer,PCa)细胞株中是否存在干细胞亚群。方法:分别用免疫表型法和侧群(side population,SP)细胞法从5种人PCa细胞株(Du145、IA8、LNCaP、TSU-PrL和PC-3)中富集类干细胞,再应用软琼脂克隆形成试验初步验证类干细胞亚群的体外生长方式及成瘤能力。选择LNCaP源SP细胞(LNCaP/SP),依次采用免疫细胞化学技术、Transwell、MTT以及裸鼠致瘤试验,分别检测其干细胞标记物的表达情况、鉴定其体外增殖和侵袭能力以及动物体内的致瘤和转移潜能。结果:5种细胞株中均难以分选出免疫表型为CD133+CD44+的细胞亚群。除PC-3外,其余4株细胞可分选出呈现典型克隆性生长特点的SP细胞。体外克隆形成率在IA8、LNCaP和TSU-PrL源SP细胞与非侧群(non-side population,NSP)细胞间有显著性差异(P<0.05)。与LNCaP/NSP相比,LNCaP/SP的体外增殖和侵袭能力显著增强,同时阳性表达整合素α2、Nanog、CD44、OCT4以及ABCG2等5种干细胞标记物。而且,LNCaP/SP的皮下成瘤率、骨转移率及瘤体体积亦显著高于LNCaP/NSP(P<0.01)。结论:SP分选法更适合富集人PCa细胞株中类干细胞,LNCaP/SP细胞是PCa细胞株LNCaP中的肿瘤干细胞(cancer stem cell,CSC)。     

胆囊癌细胞株GBC-SD类肿瘤干细胞筛选的研究

目的 筛选胆囊癌GBC-SD系中具有干细胞特性的细胞克隆.方法 在肿瘤干细胞培养基加入不同剂量的顺铂悬浮培养GBC-SD,将悬浮细胞收集后注射裸鼠,并持续瘤内注射顺铂,成瘤后取瘤内细胞继续原培养基培养,获得悬浮生长的克隆,分别测定其干细胞标志物(CD133、CD44、CD24)、耐药基因ABCG2细胞株MDR-1和转录因子OCT-4、Nanog的表达.结果 在肿瘤干细胞培养基和顺铂的筛选压力下,GBC-SD细胞能有效形成悬浮生长的克隆球,流式检测结果表明克隆球高表达CD133+(97.6%)、CD44+(77.9%),低表达CD24+(2.3%),同时表达耐药基因ABCG2和MDR-1,定量聚合酶链反应(PCR)及免疫荧光方法检测发现,与普通胆囊癌细胞株GBC-SD比较,克隆球干细胞基因OCT-4、Nanog表达分别增强266、284倍.结论 顺铂结合无血清培养基悬浮培养法筛选GBC-SD,作为一种新的干细胞分选方法,可以分离出具有肿瘤千细胞特征的胆囊癌克隆球.     

膀胱癌细胞株T24中侧群细胞的分离和功能鉴定

目的 观察膀胱癌细胞株T24中是否存在侧群(SP)细胞及其比例,并鉴定其功能.方法 利用双波长流氏细胞仪(FACS)检测T24中SP细胞的比例,并证实这些SP细胞是否具有癌干细胞的特点.结果 T24中SP细胞占34.7%;与非侧群(NSP)细胞比较,SP细胞有更强的生长增殖能力和克隆形成能力(P＜0.05),表达更高的ATP结合转运蛋白G超家族成员2(ABCG2)和干性基因,对放化疗有更强的抵抗能力,有更多的细胞处于G_0/G_1期(87.4%比63.3%,P＜0.05);分选后的sP和NSP细胞经过约10 d的常规培养,SP细胞中NSP的比例占76.2%,而NSP细胞中SP的比例只占2.6%.结论 膀胱癌细胞株T24中存在很高比例的SP细胞,而且这些SP细胞有癌干细胞的特点.     

Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations

BACKGROUND: The prostate epithelial stem cell has been proposed as the primary origin of neoplastic change in prostate cancer. However, the isolation and characterization of unexpanded prostate epithelial stem cells have proven problematic. METHODS: A prostate epithelial side population (SP) has been isolated utilizing a modified Hoechst 33342 dye efflux assay from both benign and malignant prostate tissue. CD45(-ve), integrin alpha2(+ve) Hoechst 33342 SP and NSP cells were isolated by FACS, immunophenotyped and functionally characterized in 3D culture. RESULTS: FACS analysis revealed a verapamil sensitive SP accounting for 0.93 +/- 0.12% and 0.57 +/- 0.11% of the total epithelial population from both benign and malignant prostates. The benign SP phenotype revealed a heterogeneous cell population consisting predominantly of small basal cells containing minimal cytoplasm. Conversely, the malignant SP was of undetermined acinar origin and with a complete loss of expression of the CDK2 inhibitor p21(WAF1/Cip1). In vitro androgen-enhanced 3D culture of the benign and malignant SP cells led to the production of spheroids which had acinus like morphology and expressed primitive and basal cell markers. Incorporation of the CD133 marker isolated a further SP sub-fraction accounting for 0.037 +/- 0.01% of epithelial cells. CONCLUSIONS: Our observations are consistent with the Hoechst 33342 dye efflux assay isolating a stem cell enriched population which can be further sub-fractionated by CD133 selection. Moreover, the loss of the CDK inhibitor in malignancy is consistent with the hypothesis that neoplastic change originates in the stem cell compartment.     

人肝癌细胞系MHCC97H中侧群细胞初探

目的 从人肝癌细胞系MHCC97H中分选侧群细胞,探索其形态、表型和功能特征.方法 利用流式细胞仪从MHCC97H中分选得到侧群细胞,用相差显微镜和透射电镜观察其形态学特点;Western blotting观察其ABCG2表达;用流式细胞仪评估侧群细胞与干细胞基因CD133、CD117的关系;用克隆形成实验和NOD/SCID接种实验分别观察侧群细胞体外增殖和体内成瘤情况.结果 侧群细胞体积较小,呈圆形或短梭形;侧群细胞的细胞器如线粒体、内质网等明显少于非侧群细胞;流式检测显示侧群细胞中含有CD133、CD117阳性细胞;Western blotting显示侧群细胞和非侧群细胞中均有ABCG2表达,两者无明显差异;平板克隆形成实验显示SP具有较强的克隆形成能力;体内移植实验显示2000个SP细胞即能在体内形成肿瘤.结论 肝癌细胞系MHCC97H中侧群细胞具有肿瘤干细胞样细胞的表型和特性;ABCG2可能不是决定肝癌侧群细胞表型的主要因素.     

人胆囊癌SP细胞的分离及ABCG2和Oct-4的表达

目的 探索在人胆囊癌细胞系中是否存在具有干细胞特性的SP细胞(side populationcells)以及SP细胞、非SP细胞、GBC-SD细胞系之间在耐药基因ABCG2和胚胎干细胞表面标志Cot-4表达方面的差异性.方法 采用FACS(流式激活细胞分选)技术分选出人胆囊癌SP细胞和非SP细胞.通过RT-PCR、Western blot以及流式技术来检测SP细胞、非SP细胞以及GBC-SD细胞系在ABCG2和Oct-4表达方面的差异情况.结果 人胆囊癌GBC-SD细胞系中存在着具有干细胞潜能的SP细胞.其所占的比例为(0.64±0.08)%,并且ABCG2在胆囊癌SP细胞中呈现出高表达的状态[(89.56±3.86)%],在非SP细胞中几乎不表达[(1.32±0.49)%],两者之间的差异具有统计学意义(P<0.05),在GBC-SD细胞系中呈弱表达[(12.37±1.61)%].Oer-4在三种细胞中的表达分别为:(94.87±1.40)%、(88.16±2.34)%、(90.17±1.61)%,三者之间差异没有统计学意义(P>0.05).结论 人胆囊癌的起源与肿瘤干细胞密切相关并且在胆囊癌细胞系中存在着具有干细胞特性并且高表达耐药基因ABOG2的人胆囊癌SP细胞.     

胰腺癌肿瘤干细胞对抗肿瘤药物敏感性的实验研究

目的 探讨胰腺癌肿瘤干细胞对抗肿瘤药物的敏感性.方法 FACS技术分选人胰腺癌PANC-1细胞;RT-PCR技术检测分选PANC-1细胞中CD133、ABCG2、Notch1的表达情况;MTT法检测分选细胞对抗肿瘤药物5-氟尿嘧啶和吉西他滨的耐药性.建立分选细胞的移植瘤模型,随机分为吉西他滨治疗组(n=3)和对照组(n=3),观察肿瘤生长情况,作CD133免疫组化染色.结果PANC-1细胞中含有SP亚群.SP细胞CD133、ABCG2、Notch1的mRNA的表达明显上调,non-SP细胞的表达量显著低于前者.在吉西他滨的干预下,SP细胞和non-SP细胞的OD值差异有统计学意义.而5-氟尿嘧啶的干预(10 μg/ml和100 μg/ml)则没有显著差异.移植肿瘤治疗组中CD133阳性细胞明显多于对照组(P=0.001).结论胰腺癌中存在SP亚群细胞.胰腺癌PANC-1的成瘤能力是由其中的SP亚群细胞决定的,而并非所有胰腺癌PANC-1细胞.胰腺癌肿瘤干细胞对抗肿瘤药吉西他滨具有较高耐药性.     

吉西他滨耐药人胰腺癌细胞株的建立及其与肿瘤干细胞的相关性研究

目的 建立吉西他滨耐药人胰腺癌细胞株SW1990/GZ,并探讨SW1990/GZ和胰腺癌肿瘤干细胞的相关性.方法 应用间歇浓度梯度倍增法建立吉西他滨耐药人胰腺癌细胞株SW1990/GZ;倒置显微镜下观察细胞形态;MTT法计算耐药指数(RI);荧光定量PCR检测ABCB1、ABCC1及ABCG2基因的表达水平;裸鼠皮下种植瘤试验观察SW1990和SW1990/GZ的成瘤能力;流式细胞仪通过侧群细胞(SP)法和表面特异抗原标记法(CIM4+CD24+)检测肿瘤干细胞含量.结果 在形态学上,SW1990/GZ较SW1990发生明显改变;SW1990/GZ的耐药指数是亲代SW1990的77.2倍;与亲代SW1990相比,耐药株SW1990/GZ中ABCB1、ABCC1及ABCG2的表达水平明显增高(P<0.01),裸鼠皮下成瘤能力增强(P<0.01);耐药株SW1990/GZ中SP细胞比例为(11.0±1.0)%,亲代SW1990中SP细胞比例为(4.6±0.9)%,CD44+CD24+细胞在两者中的比例分别为(8.7±0.8)%和(1.1±0.4)%(P<0.01).结论 吉西他滨耐药胰腺癌细胞株SW1990/GZ能高效富集胰腺癌肿瘤干细胞,CD44与胰腺癌获得性耐药关系密切,可能为克服胰腺癌获得性耐药提供新的治疗靶点.